Prescient Therapeutics (ASX: PTX) furthers development of novel anti-cancer targeted therapies (w/ Steven Yatomi-Clarke)

Prescient Therapeutics (ASX: PTX) managing director and chief executive officer Steven Yatomi-Clarke joins Small Caps to discuss the company’s development activities and plans for its novel targeted anti-cancer therapies. The company recently locked-in US Food and Drug Administration orphan drug status for lead candidate PTX-100 in treating T-cell lymphomas where clinical trials are showing promising results. Prescient has also topped up its cash reserves with $11.3 million raised to fund further development across its portfolio. Articles:https://smallcaps.com.au/prescient-therapeutics-ptx-100-promising-results-clinical-t-cell-lymphoma-trial/https://smallcaps.com.au/prescient-therapeutics-fda-orphan-drug-status-ptx-100-treat-t-cell-lymphomas/ For more information on Prescient Therapeutics: https://smallcaps.com.au/stocks/PTX/See omnystudio.com/listener for privacy information.